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Summary 
Escherichia  coli enterotoxin (LT) and the homologous cholera toxin (CT) are A-B toxins that 
cause travelers' diarrhea and cholera, respectively. So far, experimental live and killed vaccines 
against these diseases have been developed using only the nontoxic B portion of these toxins. 
The enzymatically active A subunit has not been used because it is responsible for the toxicity 
and it is reported to induce a negligible titer of toxin neutralizing antibodies.  We used site- 
directed mutagenesis to inactivate the ADP-ribosyltransferase  activity of the A subunit and obtained 
nontoxic derivatives of LT that elicited a good titer of neutralizing antibodies recognizing the 
A subunit. These LT mutants and equivalent mutants of CT may be used to improve live and 
killed vaccines against cholera and enterotoxinogenic E.  coli. 
H 
eat-labile  enterotoxin (LT) 1 and cholera toxin (CT) are 
homologous proteins that cause intestinal fluid accumu- 
lation (1-3). CT is produced by Vibrio cholerae and is respon- 
sible for cholera, an epidemic diarrheal disease causing over 
150,000 deaths each year (4, 5). LT is produced by enterotox- 
igenic Escherichia  coli  (ETEC),  which cause most cases of 
travelers' diarrhea, and, in developing countries, are respon- 
sible for approximately two episodes of diarrhea in each child 
per year (4). 
Both toxins are encoded by an homologous operon con- 
taining two overhpping genes coding for the A and B subunits, 
which contain the toxic and receptor binding domains, respec- 
tively (6-8).  After synthesis the two subunits are exported 
to the periplasm where they are assembled into the final struc- 
ture which contains five copies of the B subunit assembled 
in a compact ring-like structure (B oligomer), and one copy 
of the A subunit (9). As in the case of other bacterial toxins 
such as diphtheria, pseudomonas, and pertussis toxins, tox- 
icity is mediated by the ADP-ribosyltransferase activity of 
the A subunit, which modifies essential GTP-binding pro- 
teins of eukaryotic cells  (3,  10). 
The immune response to CTs  and LTs has been widely 
studied by using chemically inactivated toxoids and whole 
toxins, usually in the presence of Freund's adjuvant. These 
studies have shown that whereas immunization induces both 
1 Abbreviations used in this paper: CT, cholera toxin; ETEC, enterotoxino- 
genic E. coli; LT, E. coli heat-labile enterotoxin. 
anti-A and anti-B antibodies, toxin-neutralizing aatibodies 
are elicited almost entirely by the B subunit (11-16).  Based 
on these observations, vaccine development has been focused 
on live-attenuated (17, 18) or killed vaccines (19-21) containing 
only the nontoxic but immunogenic B subunit, and inducing 
mostly antibacterial protective immunity. The occurrence in 
Bangladesh of an outbreak caused by a strain with a different 
serotype (22, 23) against which the developed vaccines are 
ineffective, showed the weakness of this approach. Moreover, 
this emphasized the need to improve the current vaccines, 
possibly by inducing protective immunity against antigens 
such as CT, that are common to all cholera strains.  In this 
work we produced a derivative of LT that is nontoxic and 
induces  significant  neutralizing  antibodies  against  the  A 
subunit. Such a molecule and equivalent derivatives of CT 
may be useful to improve vaccines against cholera and ETEC. 
Materials and Methods 
Plasmid Construction and Mutagenesis.  The 2-kb SmaI-HindlII 
fragment from plasmid pEWD299,  containing the LT genes and 
the LT promoter region (24, 25), was subdoned into the Blue- 
Script KS vector (Stratagene, San Diego, CA) and was used in all 
subsequent studies. Site-directed mutagenesis was performed on 
single-stranded DNA, using the method of Zoller and Smith (26). 
LT-K63 was obtained using the following oligonucleotide for muta- 
genesis: 5'-GTTTCCACTAAGCTTAGTTTG-3'. LT-K7 was ob- 
tained using the oligonucleotide 5'-GATTATACAAGGCTGACT- 
3'. DNA manipulations were performed  by standard  procedures  (27). 
Protein Purification.  LT and LT mutant proteins were purified 
2147  J.  Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/94/12/2147/07  $2.00 
Volume 180  December  1994  2147-2153 from the periplasm of recombinant E. coli strains grown in a 20- 
liter fermentor, using controlled pore glass and A5M Sepharose 
columns as described by Pronk  et  al.  (24). Gel filtration on a 
Sephadex 75 column (Pharmacia  LKB, Uppsala, Sweden) was then 
used to separate the holotoxin from the free pentamer. This was 
done both on large-scale in order to obtain molecules  virtually free 
of any B pentamer, and at the analytical  level to determine the rela- 
tive abundance of fully assembled molecules and free LTB in the 
material purified  from periplasmic space. CT was purified from cul- 
ture  supernatant of a wild-type cholera strain, as described by 
Mekalanos (28). 
Immunoassays.  Western blotting was used to test the ability 
of the antibodies to recognize the A subunit, the B monomer, or 
the B pentamer. 3/~g of LT were run in each lane of a 15% poly- 
acrylamide gel. Depending on whether the sample was boiled or 
not before SDS-PAGE, the B monomer or the B pentamer, respec- 
tively,  were obtained. Sera  were usually  tested at a dilution of 1/500. 
Purified antibody fractions were usually tested diluted 1/70. Ra- 
dioimmunoassay was used to test the specificity  of the antibody 
fractions and the ability of  LT-K63 or LTB to compete for antibody 
binding with wild-type toxin. The test was performed essentially 
as described (29). Microtiter plates (Microvil  PVC microtiter plates; 
Dynatech  Laboratories,  Alexandria,  VA) were coated  with 10/~g/ml 
of purified ~/-globulins,  overnight at 4~  and then saturated with 
BSA 1% for 2 h at 37~  The assay  was performed adding to each 
well lzSI-labeled LT (10  s cpm/well of chloramine-T labeled LT) 
mixed with 10-fold dilutions of competitor protein (10-10,000 
ng/ml). After washing, the wells  were counted in a gamma counter. 
Assays were performed in duplicate. 
Toxin Activity on YI Cells.  The morphological change caused 
by LT and CT on Y1 adrenal cells (30) was used to detect the toxic 
activity  of  LT and LT mutants and to measure  the toxin-neutralizing 
titer of the antibodies. The assay  was performed in microtiter plates 
using 50,000 cells/well. The results were read after 48 h of incuba- 
tion. The assay detected 5 pg/well of wild-type toxin. In toxin 
neutralization experiments, 80 pg of  LT or CT and serial dilutions 
of antibodies were preincubated at 37~  for 3 h before they were 
added to the cells. 
Animal Immunization.  Mice  were immunized subcutaneously 
at days 0 and 15, and intraperitoneally at days 30 and 45, using 
either 3 or 25/~g of purified protein. The antigen was given in 
saline in all immunizations or mixed with Freund's adjuvant. The 
immunizations performed with Freund's adjuvant used complete 
adjuvant at day 0, incomplete adjuvant at days 15 and 30, and no 
adjuvant at day 45. Blood was taken 7 d (day 52) after the last 
immunization. Rabbits were immunized intradermally at day 0, 
subcutaneously  at day 14, and intraperitoneally at days 28 and 56. 
The antigen was either given in saline  in all immunizations  or mixed 
with complete Freund's adjuvant at day 0 and incomplete adjuvant 
at days  14, 28, and 56. Blood was taken 15 d after the last immuni- 
zation. 
Affinity Purification of Anti-A and Anti-B Antibodies.  The LTB 
subunit was purified (24) from the periplasm of an E. coli strain 
transformed with a plasmid encoding only the B subunit of LT. 
The affinity matrix was prepared by coupling 5 mg of LTB/ml of 
CNBr-activated Sepharose  4B (Pharmacia  LKB), following the in- 
structions of the manufacturer. 2 ml of serum were diluted to 6 
ml with phosphate-buffered saline and applied to a column con- 
taining 0.5 ml of resin. The flow through was collected and the 
bound fraction of antibodies were eluted by 0.1 M glycine buffer, 
pH 2.7, containing 300 mM NaC1. The eluted fractions were neu- 
tralized immediately using a 1 M Tris-HC1 buffer, pH 9. Fractions 
with an OD~m above 0.05 were collected. To ensure that all anti- 
B antibodies were removed  from the flow through, this was loaded 
again on the regenerated B column until the ODzs~m of the eluted 
fraction was equal to, or below, 0.05. To use less serum, in some 
experiments the volumes were scaled down fourfold. 
Results 
Construction of  Nontoxic Mutants of LT.  The crystallographic 
structure of ADP-ribosylating toxins (9, 31, 32) shows that 
all these enzymes have a cavity harboring the NAD-binding 
site that is delimited by a ~-strand and an o~-hdix (Fig.  1, 
bold line).  The catalytic residues  (Arg7, Glu112,  and His44 
in the case of LT) surround this cavity on both sides (Fig. 
1). To study the role of the amino acids involved in the struc- 
ture and function of the NAD-binding and catalytic site, we 
designed  and  constructed  by  site-directed  mutagenesis  a 
number of LT mutants and tested them for the ability to form 
the AB structure and for toxicity on Y1 cells. The details 
of this work are described in separate manuscripts (33, 34). 
After an initial screening, we selected for further studies LT- 
K63, a mutant that was nontoxic, well-assembled, and among 
the most resistant to proteolytic attack. In this mutant, a 
small, polar residue of the B-strand (Set 63), that is conserved 
also in CT and pertussis toxin, was changed by site directed 
mutagenesis to Lys 63. We reasoned that the large,  charged 
Lys residue would fill the NAD-binding cavity, and possibly 
stabilize the structure through salt bridges with one of the 
glutamic acids in positions 110 and 112 which face the cavity. 
The LT-K63 mutant produced in E. coli was exported to 
the periplasmic space and assembled into the A-B structure, 
at least as efficiently as the wild-type LT (Table 1), so that 
it could be purified to homogeneity  by conventional methods 
(24).  Typically, we obtained 80 mg of pure protein from a 
10-liter fermentor. The purified mutant toxin was indistin- 
guishable from wild-type LT in SDS-PAGE (Fig. 2 a), enzy- 
matically inactive in the ADP-ribosylation assay, and non- 
toxic on Y1 cells (30), even when 18 #g of protein were used 
(Table 1). Since in this assay the wild-type LT is toxic at 5 
pg, LT-K63 is at least 3.6  x  106 times less toxic than wild- 
type toxin. As expected, LT-K63 maintained the ability to 
bind the receptor ganglioside GM1, an activity that resides 
in the B pentamer. Furthermore, it was recognized both in 
competitive  radioimmunoassay and  Western  blotting  as 
efficiently as LT by a number of anti-LT polyclonal and mono- 
clonal antibodies available in the laboratory (data not shown). 
In conclusion, LT-K63 is nontoxic, but otherwise indistin- 
guishable from wild-type LT. In some of the studies, a second 
nontoxic mutant of LT was used for comparison (LT-K7). 
This mutant, containing a substitution of one of the residues 
important for catalysis shown in Fig. 1 (Arg7 ~  Lys), formed 
the AB structure less efficiently than LT, and had an A subunit 
that was more susceptible  to proteolytic attack (Table 1). 
Freund's Adjuvant Influences the Specificity  of the Immune Re- 
sponse to LT-K63.  The understanding of the immunogenicity 
of cholera and LT toxins has been complicated by both the 
toxic and the adjuvant activities of these molecules (11, 13-16). 
The availability  of a nontoxic derivative of LT provided a 
unique opportunity to study the immune response to the mol- 
ecule itself. First, mice were immunized with different doses 
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of LT-K63, with or without Freund's adjuvant, and the sera 
obtained were analyzed for antibody response to LT by Western 
blotting. As shown in Fig. 2 b (lanes I and 2), mice immunized 
with 3 #g of LT-K63 with adjuvant recognized only the B 
subunit, whereas mice immunized without adjuvant recog- 
nized only the A subunit. When 27/~g of LT-K63 were used 
for immunization (Fig. 2 b, lanes 3 and 4), the antibody re- 
sponse changed quantitatively, but a similar trend was ob- 
served: sera from mice immunized with adjuvant recognized 
mostly the B subunit and those from mice immunized  without 
Figure  1.  (a) or-Carbon structure of the active site of 
LT. The bo/d trace indicates the amino acids 58-76 folded 
in a fl-strand followed by an or-helix, which form  the 
NAD-binding site. The  catalytic  amino acids Arg7, 
Glu112, and His44 are also indicated by a bold trace. The 
intermediate trace  indicates the other sequences that are im- 
portant for NAD-binding and catalysis. The position of 
the amino acid modified in LT-K63  and LT-K7  is indicated. 
(b) Amino acid homology in the region of Ser63 between 
LT, CT (8), pertussis toxin (PT) (46), and Mosquitocidal 
toxin (MTX) (47). 
adjuvant recognized mostly the A  subunit. Immunization 
of rabbits gave results similar to those reported in Fig. 2 b. 
These results suggested that immunization in the presence 
of Freund's adjuvant may direct the immune response towards 
the B  subunit of LT. 
Fractionation of  Anti-K.63 Antibodies.  To study further the 
properties  of the antibody response  to LT, the anti-A and 
anti-B fractions of the rabbit sera were separated by at~nity 
chromatography  using  a column containing  immobilized 
recombinant B pentamer as shown schematically in Fig. 3 a. 
Table  1.  Comparison of the Properties of LT, LT-K7,  and LT-K63 
LT  LT-K7  LT-K63 
Amino acid change  /  Arg7 ~  Lys  Ser63  ~  Lys 
Codon change  /  CGT --~ AAG  TCT -~ AAG 
ADP-ribosylation  Positive at  0.5 ~g  Negative at 3.0/~g  Negative at 3.0/~g 
Percent unassembled B5  in purified 
protein*  7%  25%  2% 
Resistance to  Trypsin*  +  -  + 
Binding to  GM1  +  +  + 
Toxicity on Y1 cells  Toxic at  5 pg/ml  Nontoxic at  18 /~g/ml  Nontoxic at  18/~g/ml 
* The concentration of the free oligomer in the proteins purified from periplasm reflects the ability of the mutant A subunit to form the holotoxin (33). 
* Incubation for 5 min of 0.35 mg/ml of LT, LT-K7, and LT-K63 in the presence of 0.07 mg/ml of trypsin resulted in complete degradation  of the 
A subunit of LT-K7. The A  subunits of LT and LT-K63 and the B subunits of all mutants were unaffected by the treatment. 
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and LT-K7.  (b) Western  blotting  to detect  the anti-A  and anti-B  monomer 
antibodies. Mice  in lanes I and 2 were immunized  with 3 #g of LT-K63; 
mice in lanes 3 and 4 received  27 #g of antigen. Freund's  adjuvant  was 
used for the immunizations  shown  in lanes 1 and 3. The data reported 
were obtained  with a pool of six sera. Individual  mice were also tested 
and found to behave as shown in the figure. 
The specificity of the fractions obtained was confirmed by 
Western blotting analysis (Fig. 3 b); unfractionated sera rec- 
ognized the B pentamer, the A subunit, and the B monomer 
(Fig. 3 b, lanes 1 and 2). After passage through the B column, 
the unbound fraction contained antibodies that recognized 
only the A subunit (Fig. 3 b, lanes 3 and 4), while the frac- 
tion eluted from the column recognized only the B pentamer 
and the B monomer (Fig.  3 b, lanes 5 and 6, respectively). 
Radioimmunoassay  was then used to detect conformational 
epitopes that could be lost in Western blotting. The binding 
of t2SI-labeled LT to purified antibodies immobilized onto 
microtiter wells was completed with cold LT or recombinant 
B oligomer. As shown in Fig.  3 c (top), the antibodies that 
did not bind the B affinity column and recognized only the 
A subunit in Western blotting, also bound LT efficiently in 
this assay, but did not bind the B oligomer. These data indi- 
cate that the antibodies present in the unbound fraction of 
the column recognized only LT epitopes that are present on 
the A  subunit, or that are induced by the presence  of the 
A subunit. To simplify, these will be indicated as anti-A an- 
tibodies. As expected, the antibodies retained by the B affinity 
column recognized equally well LT and the B pentamer (Fig. 
3 c, bottom),  confirming that they were indeed specific only 
for the B  subunit. 
Toxin Neutralizing Antibodies.  Since a protective immune 
response to LT should induce toxin-neutralizing antibodies, 
we investigated the ability of the antibodies induced by LT- 
K63 to neutralize the activity of the wild-type toxin on Y1 
cells. Table 2 shows that unfractionated sera from rabbits im- 
munized with LT-K63 and Freund's adjuvant had a toxin neu- 
tralizing titer of 1/20,480, which was approximately four- 
fold higher than that present in sera from rabbits immunized 
without adjuvant, which was 1/5,120.  After passage through 
the affinity  column containing immobilized B pentamer, the 
anti-A antibodies had a neutralizing titer of 1/1,280 in sera 
obtained without adjuvant and 1/40 in sera obtained with 
Figure  3.  (a) Schematic  representation  of the method  used to separate 
the anti-A  antibodies  from  the sera. (b) Western  blotting  analysis  showing 
the specificity  of the sera fractionated  with the method  shown  in a. Each 
fraction of the serum was tested  against LT that had not been boiled  be- 
fore ehctrophoresis  in order to maintain  intact the B pentamer (lanes I, 
3, and 5), and against  LT that had been boiled  before electrophoresis  in 
order to dissociate  the B pentamer in monomeric  B subunits (lanes 2, 4, 
and 6). The B pentamer  is indicated  as B5, while  the monomeric  B subunit 
is indicated as B. Lanes 1 and 2 show the reaction of the serum before 
passage through  the B affinity  column.  Lanes  3 and 4 show the specificity 
of the serum not bound to the B column (anti-A). Lanes  5 and 6 show 
the specificity  of  the anti-B  fraction  eluted  from  the column.  (c) Radioim- 
munoassay  showing  the ability  of  LT and the B pentamer  to compete  with 
12SI-labeled LT for binding to anti-A and anti-B antibodies. 
adjuvant.  Similar results were obtained in mice (Table 2). 
Therefore, although immunization with LT-K63 and Freund's 
adjuvant induced higher neutralizing titers than immuniza- 
tion without adjuvant, in the presence  of the adjuvant the 
anti-A-neutralizing antibody titers were lower than those ob- 
tained immunizing without adjuvant. From the quantitative 
point of view, the anti-A-neutralizing antibodies represented 
0.2-3.2 and 25% of  the total antibodies, depending on whether 
immunization was performed in the presence or in the ab- 
sence of the adjuvant, respectively. These results indicate that 
when immunization is performed in the presence of Freund's 
adjuvant, the ability to induce toxin-neutralizing antibodies 
resides almost entirely in the B subunit, whereas in the ab- 
sence of the adjuvant, the A subunit also induces a significant 
fraction of toxin-neutralizing antibodies. To verify whether 
the ability to induce high titer of anti-A antibodies is a prop- 
erty unique to LT-K63, rabbits were immunized with and 
without adjuvant with wild-type LT and with LT-K7.  As 
in the case of LT-K63, immunization without adjuvant in- 
duced anti-A-neutralizing antibodies; however,  these were 
never superior to 12.5% of total neutralizing antibodies. In 
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Rabbits 
-  Adjuvant 
Mice 
+  Adjuvant  -  Adjuvant  +  Adjuvant 
Serum LT-K63  1/5,120  1/20,480  1/5,120  1/20,480 
Anti-A LT-K63  1/1,280  1/40  1/1,280  1/640 
(%0 Anti-A)  (25%)  (0.2%)  (25%)  (3.2%) 
Unfractionated  mouse and rabbit sera and of their anti-A fractions are 
the presence of adjuvant the anti-A fraction represented only 
0.2-1.5% of total neutralizing antibodies. We therefore con- 
clude that immunization with LT, KT-K63, and LT-K7 in 
the absence of adjuvant  induces a significant titer of anti- 
A-neutralizing antibodies,  and that LT-K63 appears to be 
the best molecule in doing so. In the presence of Freund's 
adjuvant, however, the anti-A-neutralizing antibodies are al- 
most absent. 
Anti-LT-A Antibodies Neutralize  CT More E.~ciently  Than 
anti-LT-B Antibodies.  Although highly homologous in amino 
acid sequence, LT and CT are known to induce antibodies 
with low cross-neutralization  activity. Since the enzymati- 
cally active moiety is the portion of the molecule that is most 
conserved between LT and CT, we expected that the anti-A 
antibodies had an increased ability to neutralize CT. To verify 
this, we compared the neutralizing activity on LT and CT 
of an anti-LT-K63  serum obtained  by immunizing with 
Freund's adjuvant which recognized almost exclusively the 
B subunit, with that of the affinity purified anti-A antibodies. 
The concentration of the antibody preparations was adjusted 
so that both of them neutralized 80 pg of LT at a dilution 
of 1/512.  When tested for neutralization  of 80 pg of CT, 
the anti-B antibodies had a titer of 1/32, whereas the anti-A 
antibodies had a titer of 1/128. This finding confirmed our 
expectation that anti-LTA antibodies are more efficient than 
anti-LTB in neutralizing CT. 
Discussion 
We have shown that nontoxic mutants of LT may be used 
to induce good titers of toxin neutralizing antibodies against 
the A subunit in mice and rabbits. This finding was unex- 
pected, since the A subunit has been generally considered un- 
able to induce neutralizing antibodies. Indeed, cholera vac- 
cines have been developed  assuming that the toxin neutralizing 
immunity resides entirely on the B subunit, and that the in 
vivo protection is mediated mostly by the antibacterial anti- 
bodies. The availability of nontoxic mutants of LT and of 
equivalent mutants of the homologous CT may provide an 
opportunity to improve vaccines against cholera and ETEC. 
The two prototypes of cholera vaccines are the CVD 103- 
HgR (17, 18, 35), a live cholera strain containing a deletion 
of the gene coding for the A subunit and the killed BS-WC 
vaccine, a vaccine containing Img of purified B subunit and 
1011 killed bacteria (19-21, 36). Both vaccines showed good 
clinical effficacy against cholera induced by 01 strains, and 
shown. 
were expected to solve the cholera problem in a definitive 
way. However, the recent epidemic of the Bengal strain 0139 
against which both vaccines are ineffective (23, 37), made 
several years of vacdne development  obsolete (22,  38). To 
generate vaccines that will cover also this strain, a great effort 
is presently dedicated to develop live and dead vaccines that 
include a mixture of 01 and 0139 cells. Nevertheless, such 
vaccines would not protect against serotypes other than 01 
and 0139 that may arise in the future, as occurred recently 
for the Bengal strain.  An alternative way to generate vac- 
cines covering the 0139 strain and possibly also new strains 
that may arise in the future, would be to improve the protec- 
tion conferred by the toxin, a molecule that is present in all 
pathogenic cholera strains and also present in ETEC. A role 
of the immunity against the B subunit of CT in protection 
against disease has been demonstrated in several instances. 
Anti-CTB antibodies are known to be synergistic.with anti- 
lipopolysaccharide antibodies in inducing protection against 
challenge with live V. cholerae (39). In the field trial in Ban- 
gladesh, during the first 6 too, protection was much higher 
(85%) in the group that received the BS-WC vaccine con- 
taining the B subunit  and bacterial cells, than in the group 
that received the bacterial cells alone (58%) (20, 40). In the 
same clinical trial, the BS-WC vaccine conferred a good pro- 
tection against diarrhea caused by LT producing ETEC, which 
are known to share only the toxin antigen with V. cholerae 
(41). In a subsequent study in travelers to Morocco, the an- 
titoxin  immunity  induced by  the  BS-WC  vaccine  was 
confirmed to protect from E. coli-induced diarrhea  (42). 
In conclusion,  the evidence that immunity against the B 
subunit can confer  protection against disease encourages the 
development of nontoxic LT and CT molecules that may in- 
crease the protection mediated by the antitoxin immunity. 
The use of a fully assembled molecule such as LT-K63, in- 
stead of the B subunit  alone would increase the ability of 
the immunity obtained  to crossneutralize cholera or other 
serological variants of LT. In addition, the nontoxic mutants 
would provide a target for the immune system larger than 
the B subunit alone. For instance, the A subunit, which is 
a polypeptide  of 239 aminoacids, should help to overcome 
the genetic restriction  that is expected with a polypeptide 
of only 105 aminoacids, such as the B subunit,  and that has 
been described in the mouse model (43). 
We have observed that LT-K63 induces a higher propor- 
tion of anti-A-neutralizing antibodies than wild-type toxin 
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clude whether this is statistically significant, it is not unlikely 
that the ability to induce anti-A-neutralizing antibodies may 
be different in different mutants. In fact, the neutralizing epi- 
topes of the A subunit are likely to be conformational and 
the ability to induce an immune response against them may 
depend on the stability of the 3-dimensional structure. Sev- 
eral observations  suggest that the Ser63 --- Lys mutation may 
increase the stability of the structure of the A subunit, and 
possibly the ability of this molecule to induce toxin neu- 
tralizing antibodies. For instance, LT-K63 is more stable than 
LT-K7 in the presence of trypsin and more efficient than LT- 
K7 and wild-type LT in assembling the holotoxin in the 
periplasm, suggesting that the A subunit of LT-K63 is con- 
formationally more competent than the wild-type to form 
a stable AB5 structure (Table 1). The crystal structure of these 
molecules, which is progress,  should help to answer some 
of these questions. Preliminary data on the structure of LT- 
K7 indicate that in this mutant, one of the loops that face 
the active site has an increased motility, which may justify 
the increased  susceptibility to proteases  of LT-K7. 
Role of Freund's  Adjuvant  in  the  Immune  Response  to LT- 
K63.  Freund's adjuvant has been generally used to enhance 
immune responses in animal immunization. The possibility 
that the use of the adjuvant could bias the specificity of the 
immune response has not been a great concern. Here we have 
shown that when a nontoxic mutant of LT is used to im- 
munize mice or rabbits,  the quality of the immune response 
is changed if Freund's adjuvant is used. In particular, the pres- 
ence of Freund's adjuvant decreases dramatically the antibody 
response  towards the A  subunit both in Western blotting 
and in toxin-neutralizing activity. This finding may explain 
the very low immunogenicity of the A subunit reported in 
the literature. The effect of Freund's adjuvant could be ex- 
plained by its hydrophobic nature that could result in the 
preferential denaturation of some epitopes.  In the case of the 
A subunit, that is known to be loosely associated to the B 
pentamer and to be able to interact with hyclrophobic mem- 
branes (44),  Freund's adjuvant may induce a change in con- 
formation and possibly the dissociation from the B pentamer. 
In general, the finding reported here for LT-K63 and re- 
cently on recombinant pertussis and diphtheria antigens (45) 
should induce a critical reevaluation of the immunogenicity 
data reported using Freund's adjuvant and a careful selection 
of the adjuvants to be used for immunization. 
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